Abstract:Resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) is often acquired in non-small cell lung cancer (NSCLC) patients during treatment. We previously demonstrated that combined treatment with EGFR-TKI gefitinib plus chemotherapy improved progression-free survival (PFS) in NSCLC patients carrying sensitive EGFR mutations. Pharmacological interaction between gefitinib and pemetrexed was evaluated in NSCLC cell line PC-9 using MTT assay. The influence of combined treatment with gefitinib plus pemetrexed on gene expression profiles and signaling pathways has been investigated using microarray and Ingenuity Pathway Analysis (IPA). Synergistic inhibitory effect between gefitinib and pemetrexed was observed in NSCLC cell line PC-9. Figure 1A suggested representative proliferation inhibitory effects of gefitinib, pemetrexed and combined treatment for 48 hours. Figure 1B showed CI values of concurrent gefitinib-pemetrexed treatment in PC-9 NSCLC cell line. CI values at ED50, ED75 and ED90 were shown. Furthermore, widespread gene expression changes and critical signaling pathways were induced significantly by combined treatment in PC-9 cells. Figure 2A was heatmap of gene expression prolifes in human NSCLC PC-9 cell line treated with gefitinib (blue), pemetrexed (purple) or gefitinib-pemetrexed combination (orange) with the criteria P<0.05 and ▏fold change ▏>1.5. Genes and samples were listed in rows and columns, respectively. A colour standard for data normalization was shown at the bottom with green representing downregulated genes while red representing upregulated genes. In Figure 2B, pathway enrichment of differential expressed genes was analysed using Ingenuity Pathway Analysis (IPA). Signaling pathways shown here were based on a P<0.0001. Figure 2C showed heatmap of critical pathways affected by combined treatment as compared to gefitinib single treatment. Heatmap colour represented the Z-score of signalling pathways. Z-score>0 meant the signalling pathway was stimulated by related treatment while Z-score<0 meant the signalling pathway was inhibited by related treatment.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Gene expression profiles revealed potential signaling pathways contributing to the synergism.

[Small Molecule Inhibitor SB203580 Enhances the Antitumor Effect of Gefitinib in PC-9 and A549 Lung Cancer Cell Lines].

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Effect of Wnt Signaling Suppression on Gefitinib in Non Small Cell Lung Cancer Cell Lines

Sequence-dependent antiproliferative effects of gefitinib combined with docetaxel in non-small cell lung cancer cells in vitro

Combined Inhibition of Insulin-Like Growth Factor-1 Receptor Enhances the Effects of Gefitinib in a Human Non-Small Cell Lung Cancer Resistant Cell Line

[Sensitivity of Two Cell Lines with Acquired Resistance to Gefitinib to Several Chemotherapeutic Drugs].

Apatinib to Enhance Antitumor Activity of Gefitinib in Non-Small Cell Lung Cancer.

Drug Resistance Mechanism of Non Small Cell Lung Cancer PC9/AB2 Cell Line with Acquired Drug Resistance to Gefitinib

Inhibition effects of gefitinib on non-small cell lung cancer cell lines in vitro

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Combined treatment with TNF-α/gefitinib alleviates the resistance to gefitinib in PC-9 cells:

EP1.03-11 Mechanisms of Gefitinib Plus Pemetrexed on Human Non-Small Cell Lung Cancer

SFI Enhances Therapeutic Efficiency of Gefitinib: an Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

Blocking the PI3K/AKT and MEK/ERK Signaling Pathways Can Overcome Gefitinib-resistance in Non-Small Cell Lung Cancer Cell Lines

Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer

Interferon-α Reduces the Gefitinib Sensitivity of Human Non-Small Cell Lung Cancer

Effects of Anti-Egfr Monoclonal Antibody Cetuximab in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib on Apoptosis of Human Pulmonary Adenocarcinoma Cells and Their Action Mechanism

Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy

P3.02b-123 Lysimachia Capillipes Capilliposide Inhibits AKT Activation and Restores Sensitivity to Gefitinib in NSCLC with Acquired Gefitinib Resistance

Induced IGF-1R Activation Contributes to Gefitinib Resistance Following Combined Treatment with Paclitaxel, Cisplatin and Gefitinib in A549 Lung Cancer Cells.